. 2012 May 24;26(4):349–358. doi: 10.1007/s10557-012-6395-z

Table 1.

Comparison of baseline lipid levels and mean common CIMT progression rates from clinical studies used to calculate the power analysis standard deviation

Study Treatment	Mean BaselineLDL-C (mg/dL)^a	Mean BaselineHDL-C (mg/dL)^a	Mean Baseline TG (mg/dL)^a	Treatment Period Duration	Mean Common CIMT Change from Baseline, mm (SD)
Taylor et al. (2004) [37]
Niacin	87	39	154	12 months	0.014 (0.104)
Placebo	91	40	172		0.044 (0.100)
Difference	91	40	172		−0.03
Sidhu et al. (2004) [44]
Rosiglitazone	98	45	114	48 weeks	−0.012 (0.094)
Placebo	102	47	137		0.031 (0.096)
Difference	102	47	137		−0.043
Hanefeld et al. (2004) [46]
Acarbose	Not	51	212	≥36 months	0.007 (0.019)^b
Placebo	reported	49	235		0.013 (0.018)^b
Difference	reported	49	235		−0.006^b
Mazzone et al. (2006) [36]
Pioglitazone	113.8	47.1	178.6	72 weeks	−0.001
Glimepiride	111.3	47.6	170.4		0.012
Difference	111.3	47.6	170.4		−0.013
Hodis et al. (2006) [42]
Troglitazone	170	50	115	24 months	0.0030 (0.021)^b
Placebo	182	50	115		0.0066 (0.021)^b
Difference	182	50	115		−0.0036^b
Hedblad et al. (2007) [41]
Rosiglitazone	135	50	150	12 months	0.01 (0.073)
Placebo	131	50	150		0.017 (0.076)
Difference	131	50	150		−0.007
Crouse et al. (2007) [34]
Rosuvastatin	155	50	126	24 months	0.0004 (0.019)^b
Placebo	154	49	134		0.0088 (0.02)^b
Difference	154	49	134		−0.0085^b
Kastelein et al. (2007) [38]
Atorvastatin	139	52	97^c	24 months	−0.0014 (0.027)^b
Atorvastatin + torcetrapib	138	53	97^c		0.0038 (0.027)^b
Difference	138	53	97^c		−0.0052^b
Kastelein et al. (2008) [43]
Simvastatin	318	47	160^c	24 months	0.0024 (0.077)
Simvastatin + ezetimibe	319	47	157^c		0.0019 (0.079)
Difference	319	47	157^c		0.0005
Hiukka et al. (2008) [31]
Fenofibrate	120	45	136	60 months	0.0050 (0.060)^b
Placebo	118	43	147		0.0069 (0.054)^b
Difference	118	43	147		−0.0019^b
Meuwese et al. (2009) [35]
Pactimibe	141	51	135	12 months	0.019 (0.099)^d
Placebo	139	52	136		0.005 (0.085)^d
Difference	139	52	136		0.014
Taylor et al. (2009) [45]
Ezetimibe	84	43	122^c	14 months	−0.0007 (0.037)
Niacin	81	43	126^c		−0.0142 (0.040)
Difference	81	43	126^c		0.0135
Davidson et al. (2009) [40]
Pomegranate juice	139	55	153	18 months	0.005 (0.048)^b
Control	142	56	144		0.005 (0.048)^b
Difference	142	56	144		0.00^b

C cholesterol; CIMT carotid intima-media thickness; HDL high-density lipoprotein; LDL low-density lipoprotein; TG triglyceride

^aReported values in mmol/L were converted to mg/dL by dividing cholesterol values by 0.02586 and TG values by 0.01130

^bChange per year

^cMedian values

^dIncluded common, bulb, and internal segments